Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain disease-causing genes through ribonucleic acid interference (RNAi), a mechanism that disrupts the production of proteins that can lead to cancer, metabolic, and infectious diseases. Tekmira's lead candidates are being developed to treat tumors and high cholesterol. It also partners with other pharmaceutical companies, such as Alnylam Pharmaceuticals and Roche, to advance additional RNAi products using Tekmira's stable nucleic acid-lipid particles (SNALP) RNAi drug delivery technology.
Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.
Herbalife Ltd. (Herbalife) is a global network marketing company that sells weight management, nutritional supplement, energy, sports and fitness products, and personal care products. Herbalife sells its products in 70 countries through a network of over 1.9 million independent distributors. The Company offers science-based products in four principal categories: weight management, targeted nutrition, energy, sports and fitness, and Outer Nutrition. In October 2008, Herbalife announced that it has begun doing business in Honduras, Nicaragua, and Guatemala. These countries become part of the Company's Mexico and Central America region. Five products from Herbalife's nutrition line will be available in each market, including the Company's flagship Formula 1 Nutritional Shake Mix, in four flavors; Performance Protein Powder; Herbal Aloe Drink Concentrate; NRG Tea, and Thermojetics Tea.
Sanjiu Enterprise Group is really into pushing drugs. Of course, being state-owned, these are drugs of the legal variety. Sanjiu Enterprise Group company operates Shenzhen 999 Chinese Medicine Investment & Development Company, which manufactures over-the-counter drugs designed to treat minor illnesses; it also produces prescription drugs like traditional Chinese injections, biomedicines, and antibiotics. Sanjiu also operates 20 other pharmaceutical subsidiaries with more than 1,000 types of herbal and other medicines in production. It markets its products under the "999" (a.k.a. "three nines", representing luck and balance in Chinese) brand; it also supplies equipment and printing services to the medical community.
Silence Therapeutics wants to put the kibosh on disease-causing genes. The company, formerly known as SR Pharma, is working in the field of RNA interference (RNAi), a cutting-edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. Its AtuPLEX drug delivery system is designed to work specifically with RNA molecules. Silence Therapeutics acquired fellow RNAi research company Intradigm in 2010, greatly expanding its RNAi program capabilities, which it hopes will make it a more attractive partner to bigger pharmaceutical companies looking to develop products based on that science.
Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.
Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.
lmmuCell Corporation company was founded in 1982 and is based in Portland, Maine. ImmuCell Corporation, an animal health biotechnology company, engages in the development, manufacture, and sale of products that improve animal health and productivity in the United States and internationally. It offers First Defense, an orally delivered scours preventive product that is manufactured from cows colostrums using proprietary vaccine and milk protein purification technologies. The company also provides products that aid in the management of inflammation of the mammary gland caused by bacterial infections, including Wipe Out Dairy Wipes, which consist of pre-moistened, biodegradable towelettes that are impregnated with Nisin to prepare the teat area of a cow in advance of milking; MASTiK, a mastitis antibiotic susceptibility test kit; and California Mastitis Test (CMT), which is performed at cow-side for early detection of mastitis. CMT can be used for bulk tank and individual cow sample monitoring, and for determining the quarter of the udder that is mastitic. In addition, it offers Rapid Johne's Test, which identifies cattle with symptomatic Johne's disease in a herd. Additionally, ImmuCell Corporation focuses on developing Mast Out, an intramammary infusion product containing Nisin for use in the treatment of mastitis in lactating dairy cows. It sells and markets its products primarily to veterinarians and producers in the dairy and beef industries.
Oxford BioMedica has no reservations about launching attacks on disease. The biotechnology company focuses on developing gene therapy treatments for oncology and neurotherapy. Its lead product,TroVax, is in testing for renal and colorectal cancer and is designed to stimulate the body's immune response to attack tumor cells. Another leading candidate, ProSavin, is in testing for treatment of Parkinson's disease. The company has several additional products in various stages of clinical development. Oxford BioMedica has awarded Sanofi-Aventis exclusive rights to develop and commercialize TroVax globally. The company's California-based BioMedica subsidiary handles its business development in North America and Asia.
Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.